Form 4: Sutro Biopharma CBO's RSU Vesting and Tax Withholding

Sutro Biopharma's Chief Business Officer, Barbara Leyman, reported the vesting of 25,000 restricted stock units and subsequent tax-related share withholding.

Summary

• Barbara Leyman, Chief Business Officer of Sutro Biopharma, Inc. (STRO), reported transactions on July 8, 2025.
• 25,000 Restricted Stock Units (RSUs) vested, converting into common stock.
• 8,944 shares of common stock were withheld by the issuer to satisfy income tax withholding and remittance obligations related to the RSU settlement, at a price of $0.78 per share.
• Following these transactions, Leyman directly owns 16,056 shares of common stock and 75,000 unvested Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing details routine executive compensation events (RSU vesting and tax withholding), which are generally neutral but reflect ongoing executive retention and alignment with company performance. No new material information impacting company fundamentals was disclosed.

Positives

• The vesting of 25,000 Restricted Stock Units indicates continued service and compensation for the Chief Business Officer, reflecting ongoing executive retention.
• The remaining 75,000 unvested RSUs provide a long-term incentive for the CBO, aligning her interests with shareholder value and future company performance.

Negatives

• The withholding of 8,944 shares for tax purposes reduces the immediate net share gain for the reporting person from the RSU vesting.

Future Outlook

The RSU vesting schedule, with 1/4th of the total award vesting annually beginning on July 8, 2025, indicates a continued long-term incentive structure for the Chief Business Officer, subject to her continued service to the Issuer.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies, detailing insider transactions. RSU vesting and subsequent tax withholding are standard executive compensation practices in the biopharma industry, designed to retain key talent and align executive interests with long-term company performance.

Comparison to Industry Standards

• Restricted Stock Unit (RSU) grants and their vesting schedules are a common form of executive compensation across various industries, including biopharma, serving as a long-term incentive mechanism.
• The practice of withholding shares to cover tax obligations upon RSU vesting is a standard and widely accepted method for managing tax liabilities in equity compensation plans, consistent with practices at comparable companies like Amgen Inc. or Gilead Sciences, Inc. for their executives.
• The specific number of shares or the total value of the RSU grant is company-specific and depends on factors such as the executive's role, company size, and performance, making a direct quantitative comparison without more context challenging.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine compensation events. It signals continued executive retention and alignment of management interests with long-term company performance.
• Employees: Reflects standard executive compensation practices within the company and industry.

Next Steps

• Future annual vesting of the remaining 75,000 Restricted Stock Units for Barbara Leyman, subject to her continued service to Sutro Biopharma, Inc.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and tax withholding) for the Chief Business Officer. It does not contain any new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. The transactions are expected and reflect standard practices for executive retention and compensation. Therefore, a 'Hold' recommendation is appropriate as there's no new catalyst for a 'Buy' or 'Sell' decision based solely on this filing.

Keywords

Sutro Biopharma, STRO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Vesting, Chief Business Officer, Barbara Leyman, Biopharma